Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Amrallah A. Mohammed; Hanna M. Ibrahim; Hanna A. Atwa; Ayman Elshentenawy; Amira Elwan

doi:10.2478/fco-2019-0005

.blurhash-client-img { display: none !important; }

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Forum of Clinical Oncology

Volume 10 (2019): Issue 2 (December 2019)

By: Amrallah A. Mohammed, Hanna M. Ibrahim, Hanna A. Atwa, Ayman Elshentenawy and Amira Elwan

Open Access

|Apr 2020

Figures & Tables

Staining of cyclin D1 and DJ-1 in benign prostatic hyperplasia and prostatic adenocarcinoma: A)Benign prostatic hyperplasia showing negative cyclin D1 staining (ABC × 400)B)High grade prostatic adenocarcinoma showing strong Cyclin D1 staining (ABC × 200)C)Benign prostatic hyperplasia showing faint DJ1 intensity (ABC × 100)D)High grade Prostatic adenocarcinoma with strong DJ1 intensity (ABC × 400)

Bar chart shows percent of relapse among different studied subpopulation of prostatic carcinoma patients.

Bar chart shows percent of hormone refractory relapse among different studied subpopulation of prostatic carcinoma patients

ROC curve for sensitivity and specificity of cyclin D1 in prediction of prostatic carcinoma

ROC curve for sensitivity and specificity of DJ-1 in prediction of prostatic carcinoma

Comparison between PC and BPH as regard cyclin D1 and DJ-1 (staining and overexpression)

	Prostatic Carcinoma (N=40)		Prostatic Hyperplasia (N=40)		p-value‡

	No.	(%)	No.	(%)
Cyclin D1 extent
Negative	2	(5%)	39	(97.5%)	< 0.001
Positive	38	(95%)	1	(2.5%)	< 0.001
DJ1 extent
Negative	6	(15%)	39	(97.5%)	< 0.001
Positive	34	(85%)	1	(2.5%)	< 0.001
Cyclin D1 extent /DJ1 extent
Negative/Negative	2	(5%)	38	(95%)	< 0.001
Negative/Positive	0	(0%)	1	(2.5%)
Positive/Negative	4	(10%)	1	(2.5%)
Positive/Positive	34	(85%)	0	(0%)
Cyclin D1 intensity
0	2	(5%)	39	(97.5%)	< 0.001
1	5	(12.5%)	1	(2.5%)
2	16	(40%)	0	(0%)
3	17	(42.5%)	0	(0%)
DJ1 intensity
0	6	(15%)	39	(97.5%)	< 0.001
1	4	(10%)	0	(0%)
2	14	(35%)	1	(2.5%)
3	16	(40%)	0	(0%)
Cyclin D1 intensity/DJ1 intensity
0/0	2	(5%)	38	(95%)	< 0.001
0/1	0	(0%)	0	(0%)
0/2	0	(0%)	1	(2.5%)
1/0	1	(2.5%)	1	(2.5%)
1/1	4	(10%)	0	(0%)
1/2	0	(0%)	0	(0%)
2/0	3	(7.5%)	0	(0%)
2/1	0	(0%)	0	(0%)
2/2	10	(25%)	0	(0%)
2/3	3	(7.5%)	0	(0%)
3/2	4	(10%)	0	(0%)
3/3	13	(32.5%)	0	(0%)
Cyclin D1 overexpression
Negative	23	(57.5%)
Positive	17	(42.5%)
DJ-1 overexpression
Negative	21	(52.5%)
Positive	19	(47.5%)

Clinicopathological features and outcome of 40 patients with prostatic carcinoma_

Characteristics	Prostatic Carcinoma (N=40)		Characteristics	Prostatic Carcinoma (N=40)

	No.	%		No.	%
Gleason score			Relapse
< 7	7	17.5%	Absent	16	40%
= 7	11	27.5%	Present	24	60%
➢7	22	55%
T			Distant metastasis
T1	5	12.5%	Absent	16	40%
T2	14	35%	Present	24	60%
T3	21	52.5%
Stage			Hormone Refractory Relapse	(N=24)
Stage I	3	7.5%	Absent	7	29.2%
Stage IIa	6	15%	Present	17	70.8%
Stage IIb	10	25%
Stage III	21	25%

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and relapse in 40 PC patients

	Prostatic Carcinoma (N=40)		Relapse				p-value

			Absent (N=16)		Present (N=24)

	No.	(%)	No.	(%)	No.	(%)
Gleason score
< 7	7	(17.5%)	7	(100%)	0	(0%)	< 0.001§
= 7	11	(27.5%)	9	(81.8%)	2	(18.2%)
➢7	22	(55%)	0	(0%)	22	(100%)
T
T1	5	(12.5%)	5	(100%)	0	(0%)	< 0.001§
T2	14	(35%)	11	(78.6%)	3	(21.4%)
T3	21	(52.5%)	0	(0%)	21	(100%)
Stage
Stage I	3	(7.5%)	3	(100%)	0	(0%)	< 0.001§
Stage IIa	6	(15%)	6	(100%)	0	(0%)
Stage IIb	10	(25%)	7	(70%)	3	(30%)
Stage III	21	(25%)	0	(0%)	21	(100%)
Cyclin D1 extent
Negative	2	(5%)	2	(100%)	0	(0%)	0.154‡
Positive	38	(95%)	14	(36.8%)	24	(63.2%)	0.154‡
DJ1 extent
Negative	6	(15%)	6	(100%)	0	(0%)	0.002‡
Positive	34	(85%)	10	(29.4%)	24	(70.6%)	0.002‡
Cyclin D1 extent /DJ1 extent
−ve/−ve	2	(5%)	2	(100%)	0	(0%)	0.003§
+ve/−ve	4	(10%)	4	(100%)	0	(0%)
+ve/+ve	34	(85%)	10	(29.4%)	24	(70.6%)
Cyclin D1 intensity
0	2	(5%)	2	(100%)	0	(0%)	0.002§
1	5	(12.5%)	5	(100%)	0	(0%)
2	16	(40%)	5	(31.3%)	11	(68.8%)
3	17	(42.5%)	4	(23.5%)	13	(76.5%)
DJ1 intensity
0	6	(15%)	6	(100%)	0	(0%)	< 0.001§
1	4	(10%)	4	(100%)	0	(0%)
2	14	(35%)	6	(42.9%)	8	(57.1%)
3	16	(40%)	0	(0%)	16	(100%)
Cyclin D1 intensity/DJ1 intensity
0/0	2	(5%)	2	(100%)	0	(0%)	< 0.001§
1/0	1	(2.5%)	1	(100%)	0	(0%)
1/1	4	(10%)	4	(100%)	0	(0%)
2/0	3	(7.5%)	3	(100%)	0	(0%)
2/2	10	(25%)	2	(20%)	8	(80%)
2/3	3	(7.5%)	0	(0%)	3	(100%)
3/2	4	(10%)	4	(100%)	0	(0%)
3/3	13	(32.5%)	0	(0%)	13	(100%)
Cyclin D1 overexpression
Negative	23	(57.5%)	16	(69.6%)	7	(30.4%)	< 0.001‡
Positive	17	(42.5%)	0	(0%)	17	(100%)	< 0.001‡
DJ1 overexpression
Negative	21	(52.5%)	16	(76.2%)	5	(23.8%)	< 0.001‡
Positive	19	(47.5%)	0	(0%)	19	(100%)	< 0.001‡

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and hormone response in 40 PC patients

	Prostatic Carcinoma (N=24)		Hormone Refractory				p-value

			Absent (N=7)		Present (N=17)

	No.	(%)	No.	(%)	No.	(%)
Gleason score
= 7	2	(8.3%)	0	(0%)	2	(100%)	1.000‡
➢7	22	(91.7%)	7	(31.8%)	15	(68.2%)	1.000‡
T
T2	3	(12.5%)	1	(33.3%)	2	(66.7%)	1.000‡
T3	21	(87.5%)	6	(28.6%)	15	(71.4%)	1.000‡
Stage
Stage IIb	3	(12.5%)	1	(33.3%)	2	(66.7%)	1.000‡
Stage III	21	(87.5%)	6	(28.6%)	15	(71.4%)	1.000‡
Cyclin D1 extent
Positive	24	(100%)	7	(29.2%)	17	(70.8%)	---
DJ1 extent
Positive	24	(100%)	7	(29.2%)	17	(70.8%)	---
Cyclin D1 extent /DJ1 extent
+ve/+ve	24	(100%)	7	(29.2%)	17	(70.8%)	---
Cyclin D1 intensity
2	11	(45.8%)	0	(0%)	11	(100%)	0.006‡
3	13	(54.2%)	7	(53.8%)	6	(46.2%)	0.006‡
DJ1 intensity
2	8	(33.3%)	0	(0%)	8	(100%)	0.054‡
3	16	(66.7%)	7	(43.8%)	9	(56.3%)	0.054‡
Cyclin D1 intensity/DJ1 intensity
2/2	8	(33.3%)	0	(0%)	8	(100%)	0.006§
2/3	3	(12.5%)	0	(0%)	3	(100%)
3/3	13	(54.2%)	7	(53.8%)	6	(46.2%)
Cyclin D1 overexpression
Negative	7	(29.2%)	7	(100%)	0	(0%)	<0.001‡
Positive	17	(70.8%)	0	(0%)	17	(100%)	<0.001‡
DJ1 overexpression
Negative	5	(20.8%)	5	(100%)	0	(0%)	<0.001‡
Positive	19	(79.2%)	2	(10.5%)	17	(89.5%)	<0.001‡

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/fco-2019-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 15 - 25

Submitted on: Aug 3, 2018

Accepted on: Jul 21, 2019

Published on: Apr 5, 2020

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Prostate carcinoma,

benign prostatic hyperplasia,

Related subjects:

Haematology, oncology

© 2020 Amrallah A. Mohammed, Hanna M. Ibrahim, Hanna A. Atwa, Ayman Elshentenawy, Amira Elwan, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 10 (2019): Issue 2 (December 2019)

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Figures & Tables

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Comparison between PC and BPH as regard cyclin D1 and DJ-1 (staining and overexpression)

Clinicopathological features and outcome of 40 patients with prostatic carcinoma_

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and relapse in 40 PC patients

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and hormone response in 40 PC patients

Paradigm

My account